ArticleNature medicine2025
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
Abstract read
In one paragraph
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart.Journal for immunotherapy of cancer · 2025Pooled it
- Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities.Journal for immunotherapy of cancer · 2026Article
- Review
- Presurgical immune biomarkers associated with pain intensity and pain interference recovery after total knee arthroplasty: findings from the PRIME-KNEE study.medRxiv : the preprint server for health sciences · 2026Article
- Enteroviral epitope mimicry enables NK cell-mediated targeting of ASPH in hepatocellular carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries.Journal for immunotherapy of cancer · 2026Article
- CMV seropositivity associates with poor clinical outcome in triple negative breast cancer.iScience · 2026Article
- Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Proanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1.The Journal of clinical investigation · 2026Article
- RhCMV expands CCR5+ memory T cells and promotes SIV reservoir seeding in the gut mucosa.JCI insight · 2026Article
- TMEM33 deletion potentiates anti-tumor CD8bioRxiv : the preprint server for biology · 2026Article
- Integrated Multi-Omics Analysis Reveals IRF1-Driven Microglial PANoptosis via ZBP1 in Spinal Cord Injury.Journal of inflammation research · 2026Article
- Review
- The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Review
- Surprising role of CMV in shaping outcomes of immunotherapy for melanoma - chronic infection yields favourable survival.Nature reviews. Clinical oncology · 2025Article
- CMV-specific clonal expansion of Th1, GZMKbioRxiv : the preprint server for biology · 2025Article
- The immune microenvironment of pathogen-associated cancers and current clinical therapeutics.Molecular cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Gusztav Milotay *MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Martin Little *MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-2592-1570
Robert A Watson *MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Dylan MuldoonMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Sophie MacKayMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Ayako KuriokaThe Centre for Human Genetics, University of Oxford, Oxford, UK.
Orion TongMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-0659-5944
Chelsea A TaylorMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Isar NassiriMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Louisa M WebbMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Oluwafemi Akin-AdigunMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Julia BremkeMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0002-2772-7675
Weiyu YeMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Bo SunMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-5507-6657
Piyush Kumar SharmaMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Ros CooperMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Sara DanielliOxford Cancer-CRUK Oxford Centre, University of Oxford, Churchill Hospital, Oxford, UK.
Flavia Matos SantoMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Alba Verge de Los AiresMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Guangyi NiuMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Lea CohenMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3971-648X
Esther NgKennedy Institute for Rheumatology, University of Oxford, Oxford, UK.
James J GilchristMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-2045-6788
Amanda Y ChongThe Centre for Human Genetics, University of Oxford, Oxford, UK.
Alex MentzerThe Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-4502-2209
Victoria WoodcockDepartment of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-7656-728X
Nicholas CoupeDepartment of Oncology, University of Oxford, Oxford, UK.
Miranda J PayneDepartment of Oncology, University of Oxford, Oxford, UK.
Michael YoudellOxford Cancer-CRUK Oxford Centre, University of Oxford, Churchill Hospital, Oxford, UK.
Mark R MiddletonDepartment of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0167-1685
Paul KlenermanThe Centre for Human Genetics, University of Oxford, Oxford, UK.
Benjamin P FairfaxMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. benjamin.fairfax@oncology.ox.ac.uk.ORCID http://orcid.org/0000-0001-7413-5002
Funding
Cancer Research UK (CRUK) DRCNPG-Nov22/100005DH | National Institute for Health Research (NIHR) ACLDH | National Institute for Health Research (NIHR) Oxford BRCWellcome TrustWellcome Trust (Wellcome) 201488/Z/16/ZWellcome Trust (Wellcome) 222426/Z/21/ZWellcome Trust (Wellcome) 226535/Z/22/ZWellcome Trust (Wellcome) BST00070
Abstract
Cytomegalovirus (CMV) is a globally endemic latent herpes virus that profoundly impacts T cell immunity. We investigated the oncological consequences of CMV infection across 341 prospectively recruited patients receiving immune checkpoint blockade (ICB) for melanoma. CMV
Indexed as
CytomegalovirusCytomegalovirus InfectionsImmune Checkpoint InhibitorsMelanomaProgrammed Cell Death 1 ReceptorAdultAgedCD8-Positive T-LymphocytesCTLA-4 AntigenFemaleHumansMaleMiddle AgedT-Box Domain ProteinsCTLA-4 AntigenImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorT-Box Domain Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.